April 14, 2023
Estimated Lung Cancer Screening Rates “Extremely Low” Across Insurance Types
Estimated rates of lung cancer screening with low-dose CT were extremely low among eligible patients across insurance types in 2017.
AJMC
Research News
Explore our curated selection of the latest breakthroughs in lung cancer research.
April 14, 2023
Estimated rates of lung cancer screening with low-dose CT were extremely low among eligible patients across insurance types in 2017.
AJMC
April 14, 2023
The phase 3 Pragmatica-Lung study has broader eligibility criteria than many other trials, expanding access to more patients and clinicians.
Cure Today
March 9, 2023
Patients with early-stage EGFR-mutated non-small cell lung cancer benefited from treatment with osimertinib, results of the phase 3 ADAURA trial showed.
Healio
March 9, 2023
Keytruda plus chemotherapy before surgery and as single agent after improved outcomes for patients with resectable non-small cell lung cancer.
Cure Today
February 25, 2023
Research study shows pacritinib has the ability to selectively target in squamous cell but does not impact normal glucose metabolism.
Daily Bruin
February 8, 2023
Removing only a portion of lobes is as effective as the traditional surgery for some patients with early-stage lung cancer.
Weill Cornell Medicine
February 1, 2023
New clinical trial shows improved survival rates and reduced risk of recurrence in patients taking a targeted therapy for NSCLC.
Yale School of Medicine
January 20, 2023
The ASCO Living Guideline for advanced non-small cell lung cancer (NSCLC) with driver alterations has gotten its first update, with data from recent studies.
Medpage Today
January 20, 2023
Deep-learning model takes a personalized approach to assessing each patient’s risk of lung cancer based on CT scans.
Massachusetts Institute of Technology
January 18, 2023
Lung cancer screening may accelerate the shift of the lung cancer stage from an advanced incurable stage toward an early curable disease, which may improve survival.
Journal of Thoracic Oncology
January 16, 2023
67% of small smoke particles in the US are due to human-ignited fires are responsible for degrade air quality, causing respiratory illnesses, and premature death.
SciTechDaily
December 12, 2022
Mirati’s new lung cancer drug Krazati, targeting KRAS mutations, secures FDA approval, offering hope for advanced NSCLC patients.
U.S. News
Learn more about:
LCFA prioritizes providing reliable information about new diagnostics, treatments, and prevention strategies, including exciting FDA-approved personalized therapies based on individual tumor biomarkers. Human-reviewed, AI-created content is used to create some of the summaries for the articles listed.